Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Location
5300 Memorial Drive, Suite 950, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 169 % -64.6%
Debt-to-equity 179 % +573%
Return On Equity -298 % -242%
Return On Assets -107 % -55.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14M shares +529%
Common Stock, Shares, Outstanding 14.1M shares +511%
Entity Public Float 9M USD -43.8%
Common Stock, Value, Issued 14K USD +600%
Weighted Average Number of Shares Outstanding, Basic 9.34M shares +279%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 16.9M USD -6.32%
General and Administrative Expense 8.87M USD -9.24%
Operating Income (Loss) -25.9M USD +7.32%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -23.2M USD +13.4%
Earnings Per Share, Basic -5 USD/shares +61.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.72M USD -54.1%
Assets, Current 9.34M USD -50.7%
Property, Plant and Equipment, Net 127K USD -47.1%
Operating Lease, Right-of-Use Asset 398K USD -20.4%
Assets 21M USD -31.9%
Accounts Payable, Current 2.71M USD +28.6%
Employee-related Liabilities, Current 2.01M USD +83.6%
Accrued Liabilities, Current 4.19M USD +26.8%
Liabilities, Current 6.9M USD +27.5%
Operating Lease, Liability, Noncurrent 326K USD -27.6%
Liabilities 21M USD +127%
Retained Earnings (Accumulated Deficit) -160M USD -17%
Stockholders' Equity Attributable to Parent 42K USD -99.8%
Liabilities and Equity 21M USD -31.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.56M USD +32.1%
Net Cash Provided by (Used in) Financing Activities 8M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 14.1M shares +511%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.44M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.72M USD -54.1%
Deferred Tax Assets, Valuation Allowance 38.6M USD +19.6%
Deferred Tax Assets, Gross 38.7M USD +19.5%
Operating Lease, Liability 478K USD -16.7%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.2M USD +13.4%
Lessee, Operating Lease, Liability, to be Paid 566K USD -20.5%
Operating Lease, Liability, Current 124K USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 164K USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD +8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 141K USD -14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 61K USD -56.7%
Operating Lease, Payments 156K USD +24.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 125K USD -3.1%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -17.9%
Share-based Payment Arrangement, Expense 1.72M USD -13.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%